What is the risk difference with mineralocorticoid receptor antagonist (95% CI) for Gynaecomastia - Spironolactone?
The risk difference with mineralocorticoid receptor antagonist (95% CI) for Gynaecomastia - Spironolactone is MODERATE (from 31 more to 177 more) due to risk of bias.